Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

14 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Endothelin Receptor Antagonists in Kidney Disease.
Martínez-Díaz I, Martos N, Llorens-Cebrià C, Álvarez FJ, Bedard PW, Vergara A, Jacobs-Cachá C, Soler MJ. Martínez-Díaz I, et al. Among authors: bedard pw. Int J Mol Sci. 2023 Feb 8;24(4):3427. doi: 10.3390/ijms24043427. Int J Mol Sci. 2023. PMID: 36834836 Free PMC article. Review.
Focal Segmental Glomerulosclerosis Patient Baseline Characteristics in the Sparsentan Phase 3 DUPLEX Study.
Trachtman H, Radhakrishnan J, Rheault MN, Alpers CE, Barratt J, Heerspink HJL, Noronha IL, Perkovic V, Rovin B, Trimarchi H, Wong MG, Mercer A, Inrig J, Rote W, Murphy E, Bedard PW, Roth S, Bieler S, Komers R. Trachtman H, et al. Among authors: bedard pw. Kidney Int Rep. 2024 Jan 28;9(4):1020-1030. doi: 10.1016/j.ekir.2024.01.032. eCollection 2024 Apr. Kidney Int Rep. 2024. PMID: 38765567 Free PMC article.
Discovery of 2-[1-(4-chlorophenyl)cyclopropyl]-3-hydroxy-8-(trifluoromethyl)quinoline-4-carboxylic acid (PSI-421), a P-selectin inhibitor with improved pharmacokinetic properties and oral efficacy in models of vascular injury.
Huang A, Moretto A, Janz K, Lowe M, Bedard PW, Tam S, Di L, Clerin V, Sushkova N, Tchernychev B, Tsao DH, Keith JC, Shaw GD, Schaub RG, Wang Q, Kaila N. Huang A, et al. Among authors: bedard pw. J Med Chem. 2010 Aug 26;53(16):6003-17. doi: 10.1021/jm9013696. J Med Chem. 2010. PMID: 20718494
Selectin inhibitors: a patent review.
Bedard PW, Kaila N. Bedard PW, et al. Expert Opin Ther Pat. 2010 Jun;20(6):781-93. doi: 10.1517/13543771003767468. Expert Opin Ther Pat. 2010. PMID: 20408735 Review.
Characterization of the novel P-selectin inhibitor PSI-697 [2-(4-chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[h] quinoline-4-carboxylic acid] in vitro and in rodent models of vascular inflammation and thrombosis.
Bedard PW, Clerin V, Sushkova N, Tchernychev B, Antrilli T, Resmini C, Keith JC Jr, Hennan JK, Kaila N, Debernardo S, Janz K, Wang Q, Crandall DL, Schaub RG, Shaw GD, Carter LL. Bedard PW, et al. J Pharmacol Exp Ther. 2008 Feb;324(2):497-506. doi: 10.1124/jpet.107.128124. Epub 2007 Nov 16. J Pharmacol Exp Ther. 2008. PMID: 18024786
2-(4-Chlorobenzyl)-3-hydroxy-7,8,9,10-tetrahydrobenzo[H]quinoline-4-carboxylic acid (PSI-697): identification of a clinical candidate from the quinoline salicylic acid series of P-selectin antagonists.
Kaila N, Janz K, Huang A, Moretto A, DeBernardo S, Bedard PW, Tam S, Clerin V, Keith JC Jr, Tsao DH, Sushkova N, Shaw GD, Camphausen RT, Schaub RG, Wang Q. Kaila N, et al. Among authors: bedard pw. J Med Chem. 2007 Jan 11;50(1):40-64. doi: 10.1021/jm060631p. J Med Chem. 2007. PMID: 17201409
14 results